题名

慢性腎臟病貧血新藥：缺氧誘導因子脯氨醯羥化酶抑制劑

并列篇名

New Drugs for Anemia in Chronic Kidney Disease: Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors

DOI

10.6200/TCMJ.202412_21(4).0003

作者

楊凱翔(Kai-Hsiang Yang)；林思雯(Si-Wen Lin)；吳宗昱(Tsung-Yu Wu)；許舒涵(Su-Han Hsu)；陳佩君(Pei-Chun Chen)

关键词

慢性腎臟病貧血 ； 鐵劑 ； 紅血球生成刺激劑 ； 缺氧誘導因子脯氨醯羥化酶抑制劑 ； anemia in chronic kidney disease ； iron supplementation ； erythropoiesis-stimulating agents (ESA) ； hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI)

期刊名称

北市醫學雜誌

卷期/出版年月

21卷4期（2024 / 12 / 30）

页次

326 - 337

内容语文

繁體中文;英文
中文摘要

目前慢性腎臟病貧血治療主要為補充鐵劑、紅細胞生成刺激素（ESA）以及紅血球輸血，但有研究表明ESA可能增加心血管事件和死亡的風險，近來發展新一代口服貧血藥物：缺氧誘導因子脯胺酸羥化酶抑制劑（hypoxia-inducible factor prolyl hydroxylase inhibitors, HIF-PHI），目前已在一些國家核准上市，可刺激體內紅血球生成素生成及提高鐵的利用，臨床上希望以HIF-PHI口服製劑取代ESA針劑治療，以增加病人順從性、避免ESA的風險，未來可望成為貧血治療的新選擇，本篇文章統整介紹慢性腎臟病貧血定義、評估標準、藥物治療與近年發展的新藥HIF-PH抑制劑。
英文摘要

At present, anemia in chronic kidney disease is treated with iron supplementation, erythropoiesis-stimulating agents (ESAs), or red blood cell transfusions. Some studies suggest that ESAs may increase the risk of cardiovascular events and death. Recently, hypoxia-inducible factors prolyl hydroxylase inhibitors (HIF-PHIs) - the new generation of oral anemia drugs, have been approved in some countries. HIF-PHIs can stimulate erythropoietin production and improve iron utilization. HIF-PHI oral preparations are hoped to substitute the traditional ESA treatment to increase patient compliance and avoid ESA risk and are expected to become a new option for anemia treatment. This article presents an overview of the definition, evaluation criteria, current drug treatments, and newly developed HIF-PHs for anemia in chronic kidney disease.
主题分类 醫藥衛生 > 醫藥衛生綜合
参考文献
  1. BikbovB,PurcellCA,LeveyAS,etal. Global,regional,andnationalburdenof chronickidneydisease,1990-2017:asystematic analysisfortheGlobalBurdenofDisease Study2017.Lancet2020;395(10225):709-33.
    連結：
  2. PortolésJ,MartínL,BrosetaJ.J,CasesA. Anemiainchronickidneydisease:from pathophysiologyandcurrenttreatments,to futureagents.FrontMed(Lausanne)2021;8: 642296.
    連結：
  3. MacdougallIC,WhiteC,AnkerSD,etal. Intravenousironinpatientsundergoingmaintenance hemodialysis.NEnglJMed2019; 380(5):447-58.
    連結：
  4. SnookJ,BhalaN,BealesI.L,etal.British SocietyofGastroenterologyguidelinesforthe managementofirondeficiencyanaemiain adults.Gut2021;70(11):2030-51.
    連結：
  5. BohliusJ,BohlkeK,CastelliR,etal.Management ofcancer-associatedanemiawith erythropoiesis-stimulatingagents:ASCO/ASH clinicalpracticeguidelineupdate.Bloodadv 2019;3(8):1197-210.
    連結：
  6. RobertDeicher,WalterHHörl.Differentiating factorsbetweenerythropoiesis-stimulating agents:aguidetoselectionforanaemiaof chronickidneydisease.Drugs2004;64(5): 499-509.
    連結：
  7. HermansonT,BennettC.L,MacdougallI.C.Peginesatideforthetreatmentofanemiaduetochronickidneydisease–anunfulfilledpromise.ExpertOpinDrugSaf2016;15(10):1421-6.14.FishbaneS,SchillerB,LocatelliF,etal.
    連結：
  8. FishbaneS,SchillerB,LocatelliF,etal.Peginesatideinpatientswithanemiaundergoing hemodialysis.NEnglJMed2013;368(4): 307-19.
    連結：
  9. MacdougallI.C,ProvenzanoR,SharmaA, etal.Peginesatideforanemiainpatientswith chronickidneydiseasenotreceivingdialysis. NEnglJMed2013;368(4):320-32.
    連結：
  10. AgarwalAK,YeeJ.Hepcidin.AdvChronic KidneyDis2019;26(4):298-305.
    連結：
  11. LeeP,ChandelNS,SimonMC.Cellularadaptation tohypoxiathroughhypoxiainducible factorsandbeyond.NatRevMolCellBiol 2020;21(5):268-83.
    連結：
  12. ProvenzanoR,SzczechL,LeongR,etal.Efficacy andcardiovascularsafetyofroxadustat fortreatmentofanemiainpatientswithnon– dialysis-dependentCKD:Pooledresultsof threerandomizedclinicaltrials.ClinJAmSoc Nephrol2021;16(8):1190-200.
    連結：
  13. BarrattJ,SulowiczW,SchömigM,etal.Efficacy andcardiovascularsafetyofroxadustat indialysis-dependentchronickidneydisease: pooledanalysisoffourphase3studies.Adv Ther2021;38(10):5345-60.
    連結：
  14. ChertowGM,PergolaPE,FaragYM,etal. Vadadustatinpatientswithanemiaandnon– dialysis-dependentCKD.NEnglJMed2021; 384(17):1589-600.
    連結：
  15. EckardtKU,AgarwalR,AswadA,etal. Safetyandefficacyofvadadustatforanemia inpatientsundergoingdialysis.NEnglJMed 2021;384(17):1601-12.
    連結：
  16. SinghAK,CarrollK,McMurrayJJ,etal. Daprodustatforthetreatmentofanemiain patientsnotundergoingdialysis.NEnglJMed 2021;385(25):2313-24.
    連結：
  17. SinghAK,CarrollK,PerkovicV,etal.Daprodustat forthetreatmentofanemiainpatients undergoingdialysis.NEnglJMed2021; 385(25):2325-35.
    連結：
  18. Haemoglobinconcentrationsforthediagnosis ofanaemiaandassessmentofseverity/ WorldHealthOrganization.CitedFeb3, 2023.Availableat:https://apps.who.int/iris/ handle/10665/85839.
  19. Treatmentofanemiainnondialysischronic kidneydisease/Uptodate.CitedFeb3,2023. Availableat:https://www.uptodate.com/contents/ treatment-of-anemia-in-nondialysischronic- kidney-disease.
  20. Causesanddiagnosisofirondeficiencyand irondeficiencyanemiainadults/Uptodate. CitedApril21,2023.Availableat:https:// www.uptodate.com/contents/causes-and-diagnosis- of-iron-deficiency-and-iron-deficiencyanemia- in-adults?search=Iron%20deficiency% 20anemia&source=search_result&selectedT itle=1~150&usage_type=default&display_ rank=1.
  21. Treatmentofirondeficiencyinpatientswith nondialysischronickidneydisease(CKD)/ Uptodate.CitedFeb3,2023.Availableat: https://www.uptodate.com/contents/treatmentof- iron-deficiency-in-patients-with-nondialysis- chronic-kidney-disease-ckd?search= 4.%09Treatment%20of%20iron%20deficiency% 20in%20dialysis%20patients. Treatment%20of%20iron%20deficiency%20 in%20nondialysis%20chronic%20kidney%20 disease&source=search_result&selectedTitle= 1~150&usage_type=default&display_rank=1.
  22. Blooddonorscreening:Overviewofrecipient anddonorprotections/Uptodate.Cited April21,2023.Availableat:https://www.uptodate. com/contents/blood-donor-screeningoverview- of-recipient-and-donor-protections? search=RISKS%20FROM%20A%20TRANSFUSION% 20Hemochromatosis&source= search_result&selectedTitle=4~150&usage_ type=default&display_rank=4.
  23. ManagementofAnemiainChronicKidney Disease:Revisited/TheAssociationofPhysicians ofIndia.CitedFeb3,2023.Available at:https://apiindia.org/uploads/pdf/medicine_ update_2017/mu_125.pdf.
  24. The2019NobelPrizeinPhysiologyorMedicine/ nobelprize.org.CitedFeb3,2023. Availableat:https://www.nobelprize.org/ uploads/2019/10/press-medicine2019.pdf.
  25. NobelPrizeinPhysiologyorMedicine2019: HowCellsSenseandAdapttoOxygenAvailability/ Wikimedia/Dr.GuidoHegasy.Cited Feb3,2023.Availableat:https://commons. wikimedia.org/wiki/File:HIF_Nobel_Prize_ Physiology_Medicine_2019_Hegasy_ENG. png.
  26. StatusonFDAAdvisoryCommitteevote onroxadustatinanemiaofchronickidney disease/AstraZeneca.CitedFeb3,2023.Available at:https://www.astrazeneca.com/mediacentre/ press-releases/2021/status-on-us-fdaadvisory- committee-for-roxadustat.html.
  27. AkebiaTherapeuticsreceivesComplete ResponseLetterfromtheFDAforvadadustat forthetreatmentofanemiaduetochronic kidneydiseaseinadultpatients/akebia.Cited Feb3,2023.Availableat:https://ir.akebia. com/news-releases/news-release-details/akebia- therapeutics-receives-complete-responseletter- fda.
print cancel